This expert consensus document provides comprehensive guidance on the diagnosis and management of arrhythmias and conduction disorders in cancer patients and survivors.
Advances in cancer therapeutics have significantly improved patient survival; however, cardiotoxic effects-including arrhythmias-have emerged as a growing clinical concern. This expert opinion, developed by the Working Groups on Cardio-Oncology and Electrophysiology of the Hellenic Cardiological Society, aims to raise awareness of the increasing burden of arrhythmias in cancer patients and survivors. This document explores the multifactorial etiology of arrhythmias in this population, including patient-related factors, the direct effects of malignancy, and the arrhythmogenic potential of therapies such as classical chemotherapy, targeted agents, immunotherapy, hormonal treatments, and radiotherapy. Additionally, the often-overlooked contributors-such as autonomic dysfunction and drug-drug interactions- are discussed and emphasis is put on specific diagnostic and management challenges. It provides practical insights into the spectrum of arrhythmias and conduction disorders, including atrial fibrillation, QTc prolongation, and sudden cardiac death, while underscoring the importance of comprehensive cardiologic assessment throughout the cancer care continuum.
Keramida et al. (Mon,) studied this question.